Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
How would you (non-surgically) approach and treat two synchronous distinct oropharynx T1-T2N0 primaries with definitive RT?
Would you add concurrent systemic therapy with radiation due to concern for field cancerization?
Answer from: Radiation Oncologist at Academic Institution
RT to oropharynx and bilateral neck. I can’t imagine that both are lateralized to one side. If so, one cancer. No chemo.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
No.
Sign in or Register to read more
9966
9969
Related Questions
Would you recommend adjuvant radiation for a patient with head/neck merkel cell carcinoma following a pathologic complete response to neoadjuvant immunotherapy?
For a patient s/p TORS with indications for adjuvant radiation, how does your management change with persistently elevated ctHPVDNA?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
What is the role of radiation therapy for Kimura's disease of the parotid and neck?
How would you approach a patient with synchronous HPV-mediated bilateral tonsil primary with ipsilateral lymph nodes who cannot receive chemotherapy?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?
Is there a scenario in which you would consider observation for T4a SCC involving the mandible?
What are your top takeaways in Head & Neck Cancers from ASTRO 2024?
How do you manage a twice-recurrent mucinous adenocarcinoma of the lower eyelid with direct involvement of the lateral rectus muscle and lacrimal duct?
What is the role of adjuvant RT for metastatic RCC to the thyroid resected with high-risk features?